These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24138637)

  • 1. Anti-IL-12/23 in Crohn's disease: bench and bedside.
    Niederreiter L; Adolph TE; Kaser A
    Curr Drug Targets; 2013 Nov; 14(12):1379-84. PubMed ID: 24138637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation.
    Abraham C
    N Engl J Med; 2024 Jul; 391(3):275-277. PubMed ID: 39018537
    [No Abstract]   [Full Text] [Related]  

  • 4. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.
    Fuss IJ; Becker C; Yang Z; Groden C; Hornung RL; Heller F; Neurath MF; Strober W; Mannon PJ
    Inflamm Bowel Dis; 2006 Jan; 12(1):9-15. PubMed ID: 16374252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
    Deepak P; Sandborn WJ
    Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease.
    Globig AM; Sommer NP; Wild K; Schardey J; Zoldan K; Thomann AK; Schulte LA; Schreiner R; Reindl W; Klaus J; Schempp CM; Hofmann M; Thimme R; Boettler T; Hasselblatt P
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):1-12. PubMed ID: 32679193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on ustekinumab for the treatment of Crohn's disease.
    Leung Y; Panaccione R
    Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.
    Espígol-Frigolé G; Planas-Rigol E; Lozano E; Corbera-Bellalta M; Terrades-García N; Prieto-González S; García-Martínez A; Hernández-Rodríguez J; Grau JM; Cid MC
    Front Immunol; 2018; 9():809. PubMed ID: 29731755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab for the treatment of Crohn's disease.
    Khanna R; Feagan BG
    Immunotherapy; 2013 Aug; 5(8):803-15. PubMed ID: 23902548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab: moving the target from psoriasis to Crohn's disease.
    Settesoldi A; Coppola M; Rogai F; Annese V
    Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):5-13. PubMed ID: 24410468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can IL-23 be a good target for ulcerative colitis?
    Allocca M; Furfaro F; Fiorino G; Gilardi D; D'Alessio S; Danese S
    Best Pract Res Clin Gastroenterol; 2018; 32-33():95-102. PubMed ID: 30060945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycobacterium abscessus Infection During Ustekinumab Treatment in Crohn's Disease: A Case Report and Review of the Literature.
    Shim HH; Cai SCS; Chan W; Low JGH; Tan HH; Ling KL
    J Crohns Colitis; 2018 Nov; 12(12):1505-1507. PubMed ID: 30169620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

  • 16. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab to treat Crohn's disease.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2017 Dec; 40(10):688-698. PubMed ID: 29042094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab: a novel therapeutic option in Crohn's disease.
    Simon EG; Samuel S; Ghosh S; Moran GW
    Expert Opin Biol Ther; 2016 Aug; 16(8):1065-74. PubMed ID: 27341173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab for the treatment of Crohn's disease.
    Hansen T; Targownik LE
    Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.